Claims

1. A compound of formula (IA) or (IB) or a salt, N-oxide, hydrate or solvate thereof:

wherein

Ar is an aryl or heteroaryl radical which is linked via a ring carbon, and which is substituted by a hydroxy group on a carbon in the 2-position, and which is otherwise either unsubstituted or optionally substituted;

R<sub>1</sub> is hydrogen or optionally substituted C<sub>1</sub>-C<sub>6</sub> alkyl;

 $R_2$  is hydrogen, optionally substituted cycloalkyl, cycloalkenyl,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkynyl; or a carboxyl, carboxamide or carboxyl ester group; and

R₃ is a carboxamide group.

- 2. A compound as claimed in claim 1 wherein Ar is a 2-hydroxyphenyl group which is optionally further substituted.
- 3. A compound as claimed in claim 1 wherein Ar is a 2-hydroxyphenyl group further substituted by one or more of hydroxy, ethyl, isopropyl, chloro, bromo, or phenyl groups.

- 4. A compound as claimed in claim 1 wherein Ar is a 2,4-dihydroxy-5-chlorophenyl group.
- 5. A compound as claimed in any of the preceding claims wherein R<sub>1</sub> and R<sub>2</sub> are independently hydrogen, methyl, ethyl, n- or iso-propyl, or hydroxyethyl.
- 6. A compound as claimed in any of claims 1 to 4 wherein  $R_1$  is hydrogen and  $R_2$  is hydrogen or methyl.
- 7. A compound as claimed in any of the preceding claims wherein  $R_3$  is a carboxamide group of formula  $-CONR^B(Alk)_nR^A$  wherein

Alk is an optionally substituted divalent alkylene, alkenylene or alkynylene radical,

n is 0 or 1,

R<sup>B</sup> is hydrogen or a C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>2</sub>-C<sub>6</sub> alkenyl group

R<sup>A</sup> is hydroxy or an optionally substituted carbocyclic or heterocyclic group.

- 8. A compound as claimed in claim 7 wherein Alk is  $-CH_2$ -,  $-CH_2CH_2$ -,  $-CH_2$ -,
- 9. A compound as claimed in claim 7 or claim 8 wherein  $R^A$  is phenyl, optionally substituted by at least one of OH, CH<sub>3</sub>O-, Cl, F, NH<sub>2</sub>CO-, NH<sub>2</sub>CO-, CH<sub>3</sub>NHCO--COOH, -COOCH<sub>3</sub>, -CH<sub>2</sub>COOH, -CH<sub>2</sub>COOCH<sub>3</sub>, -CH<sub>3</sub>,-CF<sub>3</sub>, -SO<sub>2</sub>CH<sub>3</sub>, -SO<sub>2</sub>NH<sub>2</sub>, 3,4-methylenedioxy and 3,4-ethylenedioxy.

- 10. A compound as claimed in any claim 7 wherein  $R_1$  and  $R_2$  are hydrogen, Ar is a 2,4-dihydroxy-5-chlorophenyl group, Alk is  $-CH_{2^-}$ , n is 0 or 1,  $R^B$  is hydrogen, and  $R^A$  is phenyl, optionally substituted by at least one of OH,  $CH_3O_-$ , CI, F,  $NH_2CO_-$ ,  $NH_2CO_-$ ,  $CH_3NHCO_-$ - $COOCH_3$ ,  $-CH_2COOCH_3$ ,  $-CH_3$ ,  $-CF_3$ ,  $-SO_2CH_3$ ,  $-SO_2NH_2$ , 3,4-methylenedioxy and 3,4-ethylenedioxy.
- 11. A compound as claimed in claim 7 wherein R<sup>A</sup> and R<sup>B</sup> taken together with the nitrogen to which they are attached form an N-heterocyclic ring which optionally contains one or more additional hetero atoms selected from O, S and N, and which is optionally substituted on one or more ring C or N atoms.
- 12. A compound as claimed in claim 11 wherein R<sup>A</sup> and R<sup>B</sup> taken together with the nitrogen to which they are attached form a morpholino, piperidinyl, piperazinyl or N-phenylpiperazinyl ring, which is optionally substituted on one or more ring C or N atoms.
- 13 A compound as claimed in claim 1 which is a member of the group consisting of
- 3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid (4-acetyl-phenyl)-amide,
- 3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid phenyl-amide,
- 3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid (4-methoxy-phenyl)-amide,
- 3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid (4-chloro-phenyl)-amide,
- 3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid (4-acetylamino-phenyl)-amide,
- 3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid 4-sulfamoyl-benzylamide,
- 3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid (4-methoxy-phenyl)-amide,

- 3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid (4-chloro-phenyl)-amide,
- 3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid (4-acetylamino-phenyl)-amide,
- 3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid 4-sulfamoyl-benzylamide,
- 3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid (4-carbamoyl-phenyl)-amide,
- 4-({[3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carbonyl]-amino}-methyl)-benzoic acid.
- 3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid 4-methyl-benzylamide,
- 3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid 4-methoxy-benzylamide,
- 3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid 4-fluoro-benzylamide,
- 3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid 4-chloro-benzylamide,
- 3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid 3-methoxy-benzylamide,
- 3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid 3-trifluoromethyl-benzylamide,
- 3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid 4-methanesulfonyl-benzylamide, and salts, N-oxides, hydrates and solvates thereof.
- 14. A method of treatment of diseases or conditions responsive to inhibition of HSP90 activity in mammals, in particular in humans, which method comprises administering to the mammal an effective amount of a compound as claimed in any of the preceding claims.
- 15. A compound as claimed in any of claims 1 to 13, for use in human or veterinary medicine.

- 16. A compound as claimed in any of claims 1 to 13, for use in the treatment of diseases or conditions responsive to inhibition of HSP90 activity.
- 17. The use of a compound as claimed in any of claims 1 to 13 in the preparation of an agent for the management of diseases or conditions responsive to inhibition of HSP90 activity.
- 18. A method as claimed in claim 14, a compound for use as claimed in claim 15 or claim 16, or the use as claimed in claim 17 wherein the disease or condition is cancer.
- 19. A method as claimed in claim 14, a compound for use as claimed in claim 15 or claim 16, or the use as claimed in claim 17 wherein the disease or condition is a viral disease, transplant rejection, inflammatory disease, asthma, multiple sclerosis, Type I diabetes, lupus, psoriasis, inflammatory bowel disease, cystic fibrosis, angiogenesis-related disease, diabetic retinopathy, haemangioma, or endometriosis.